Original Research

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma

Daniel R. McGowan a,b,1, Michael Skwarski a,c,1, Kevin M. Bradley d, Leticia Campo a, John D. Fenwick e, Fergus V. Gleeson a,d, Marcus Green a, Amanda Horne c, Timothy S. Maughan a, Mark G. McCole f, Seid Mohammed g, Ruth J. Muschel a, Stasya M. Ng h, Niki Panakis c, Remko Prevō a, Victoria Y. Strauss g, Robert Stuart c, Eliana M.C. Tacconi a, Katherine A. Vallis a,c, W. Gillies McKenna a, Ruth E. Macpherson d, Geoff S. Higgins a,c,*

a Department of Oncology, University of Oxford, Oxford, United Kingdom
b Radiation Physics and Protection, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
c Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
d Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
e Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
f Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
g Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
h Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, United Kingdom

Received 18 February 2019; accepted 11 March 2019
Available online 13 April 2019

KEYWORDS
Phase I trial; PI3K inhibitor; NSCLC; Radiotherapy; Tumour hypoxia; FMISO PET-CT

Abstract Background: Pre-clinically, phosphoinositide 3-kinase (PI3K) inhibition radiosensitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia.

Methods: This was a 3 + 3 dose escalation and dose expansion phase I trial in patients with advanced NSCLC. Buparlisib dose levels were 50 mg, 80 mg and 100 mg once daily orally for 2 weeks, with palliative thoracic radiotherapy (20 Gy in 5 fractions) delivered during week 2.
1. Introduction

Radiotherapy is used in half of patients with cancer [1]; however, tumour response and treatment efficacy are highly variable. In locally advanced non-small cell lung carcinoma (NSCLC), outcomes following standard radical (chemo)radiotherapy remain exceptionally poor with 5-year overall survival only in the region of 15% [2]. It is well recognised that suboptimal locoregional control contributes to such poor outcomes [3] and that the development of novel radiosensitisers represents an unmet clinical need for this patient group.

Intracellular signal transduction pathways are known to play an important role in determining tumour response to radiation, thus providing opportunity for developing radiosensitisers [4]. In particular, the well-studied EGFR/Ras/PI3K/Akt pathway appears to be pivotal. Aberrant activation of this pathway is common in many tumour types, including NSCLC, and correlates with poor clinical outcomes [5–7]. In vitro radiosensitivity studies demonstrate that activation of Ras, PI3K or Akt results in marked resistance of tumour cell lines to radiation, whereas inhibition improves response [8].

The importance of the EGFR/Ras/PI3K/Akt pathway in modifying the tumour microenvironment to alter radiation response has also become apparent, specifically with regard to oxygenation. In vivo experiments have shown that inhibitors of EGFR, Ras, PI3K and Akt result in marked ‘normalisation’ of tumour microvasculature with durable increases in perfusion and alleviation of tumour hypoxia [9,10]. Hypoxic regions are a common feature of solid tumours and result from an imbalance between high oxygen demand and poor oxygen delivery because of dysfunctional tumour vasculature [11]. Hypoxia is associated with an aggressive tumour phenotype and treatment resistance, which is especially pertinent for radiotherapy [12]. There is therefore significant interest in developing hypoxia modifiers as radiosensitisers and the ability of PI3K inhibitors to reduce tumour hypoxia represents a novel class of agents for this purpose. In vivo experiments have demonstrated that PI3K inhibition results in significant tumour growth delay after radiation because of vascular remodelling which is independent and synergistic to increasing intrinsic radiosensitivity [13].

Buparlisib (BKM120) (Novartis International AG, Switzerland) is an oral pan class I PI3K inhibitor. In xenografts, buparlisib reduces tumour hypoxia through rapid vascular remodelling [13]. In vitro studies have also demonstrated that buparlisib inhibits tumour mitochondrial oxygen consumption, thereby further contributing to hypoxia modification [14]. Clinical studies using buparlisib have been conducted in a range of tumour types, with established favourable pharmacokinetics, acceptable toxicity and mixed response rates [15–17]. Although buparlisib has significant potential to improve radiotherapy response, no previous trials have combined this agent with radiation.

We therefore conducted a phase I clinical trial of buparlisib with thoracic radiotherapy. The primary aim of this study was to investigate the safety and maximum tolerated dose (MTD) of buparlisib in combination with palliative radiotherapy. Palliative radiotherapy was chosen as there were no previous reports of combining this agent with radiation and because of the significant toxicity of radical radiotherapy in NSCLC. This study also investigated the effect of buparlisib on tumour hypoxia, using 18F-fluoromisonidazole (FMISO) positron-emission tomography—computed tomography (PET-CT). The use of radiolabelled tracers such as FMISO has become the most widely used method for the clinical study of tumour hypoxia. This non-invasive method correlates with other measures of hypoxia, is highly reproducible and functions as a predictive biomarker of radiotherapy outcomes [18–20].
Our findings provide clinical evidence for the safety of combining PI3K inhibition with thoracic radiotherapy and for the effect of this class of agents on tumour hypoxia in NSCLC.

2. Materials and methods

2.1. Study design

This was a single-centre (Oxford Cancer Centre), open-label, dose escalation and expansion phase I clinical trial (EudraCT number: 2012-003762-40). All patients provided written consent and trial conduct complied with the Declaration of Helsinki. Ethical approval was obtained from National Research Ethics Service Committee South Central Oxford B (12/SC/0674).

Dose escalation of oral once daily (OD) buparlisib followed a standard 3 + 3 design with three predetermined dose cohorts: cohort 1 50 mg, cohort 2 80 mg and cohort 3 100 mg. Primary end-points assessed the safety and determined the MTD of buparlisib when combined with palliative thoracic radiotherapy. The MTD was defined as the dose at which no more than 0 of 3 patients or 1 of 6 patients experienced a dose limiting toxicity (DLT). Dose escalation was not permitted beyond 100 mg OD as this dose has previously been established as the single agent MTD [15]. Once the MTD was determined, this dose was used in an expansion cohort of 6 patients with data from all trial patients used to investigate the effect of buparlisib on tumour hypoxia and perfusion after 1 week of treatment (secondary trial end-points). The trial schema is shown in Fig. 1.

2.2. Patients

Patients aged ≥18 years with life expectancy of ≥16 weeks, Eastern Cooperative Oncology Group Performance Status of 0–2, histologically confirmed advanced stage NSCLC and a thoracic lesion requiring palliative radiotherapy were eligible. Key exclusion criteria were uncontrolled central nervous system metastases, poorly controlled diabetes mellitus, psychiatric illness, cardiac disease or other malignancy (other than NSCLC) in the last three years. Anti-cancer therapy within 28 days; previous thoracic radiotherapy or exposure to PI3K, mTOR, or Akt inhibitors was not permitted. Full details of the study design including eligibility criteria can be found in the trial protocol provided as Supplementary information.

2.3. Treatment regimen

Oral buparlisib was administered OD for 14 days with palliative thoracic radiotherapy delivered during the second week. For radiotherapy planning, patients underwent CT simulation with gross tumour volume outlined and 2 cm margin added for field edge. Treatment was delivered using parallel 6 or 15 MV photon beams, and 20 Gy in 5 daily fractions was prescribed according to International Commission on Radiation Units (ICRU 62) guidance. As palliative radiation was used, no dose constraints were specified.

2.4. Assessments

Adverse events (AEs) were graded according to the National Cancer Institute’s Common Terminology Criteria (NCI CTCAE version 4.0). DLT was defined as follows: ≥grade 3 non-haematological toxicity (excluding nausea, vomiting or diarrhoea) that required hospitalisation or which did not resolve to ≤grade 2 within 7 days, ≥grade 3 nausea, vomiting or diarrhoea that persisted for >48 h, ≥grade 3 pneumonitis, ≥grade 4 haematological toxicity and grade ≥3 mood change if baseline score was 2 in the self-reported PHQ-9 or GAD-7 mood questionnaire or grade ≥2 mood change if baseline score was ≤1. DLT was considered if toxicity...
was attributable to buparlisib or its interaction with radiotherapy. Tumour response was the change in tumour hypoxic volume (HV) as detected by FMISO PET-CT performed at baseline and on day 8 of buparlisib, before radiotherapy. Patients were imaged using a Discovery 690 or 710 PET-CT scanner (GE Healthcare). 370 MBq of FMISO (University of Cambridge, UK) was injected and a 10-min image acquired 4 h after injection. CT was performed for localisation and PET attenuation correction. Tumour outlining was performed by an experienced PET-CT radiologist. Background mean standardised uptake (SUVmean) was obtained by outlining blood in the descending aorta. To determine HV, voxel-by-voxel SUVs were divided by the background SUVmean providing tumour-to-blood ratio (TBR) values, and voxels with TBR ≥1.4 were classified hypoxic, as previously described [21]. Volumes of hypoxic voxels before and after buparlisib were compared and ≥10% reduction in HV was defined as a response. This cutoff was based on reproducibility test-retest data for FMISO imaging [20] and used the minimum detectable change (MDC) method [22]. Okamoto et al. showed a mean difference of 2.7% and SD 14% in tumour-to-muscle (TMR) volumes from FMISO scans repeated within 48 h (n = 9, excluding two patients with TMR volumes <1.5 mL) [20]. MDC is the smallest change at 95% confidence interval and is defined as the standard error (4.7) multiplied by 1.96, giving 9.2%. Our ≥10% threshold was ratified by the University’s independent Early Phase Trial Oversight Committee in combination with an external radiologist.

Changes in tumour perfusion were also investigated using perfusion CT (pCT) imaging. The pCT technique used is provided as Supplementary methodology.

2.5. Statistical analysis

Patients were evaluable for DLT analysis after 14 days of buparlisib if they completed 56 days of evaluation or withdrew early after experiencing DLT. Patients who withdrew early for other reasons were deemed non-evaluable and were replaced. All patients who received
a dose of buparlisib were included in the safety analysis, for which descriptive statistics were used.

Secondary end-point analysis included all patients who had an interpretable pair of FMISO PET-CT scans. Patients with insufficient baseline HV (<1.5 mL) to reliably measure change were excluded. The number of hypoxia or perfusion responders, median response per cohort and waterfall plots were used to summarise the data. Analysis was undertaken using Stata v15.0 (StataCorp, College Station, TX).

3. Results

From June 2013 to August 2017, 21 patients were recruited. Eleven patients were registered for dose escalation with 9 evaluable for DLT analysis. Ten patients were registered during dose expansion, and in total, 15 patients were evaluable for tumour response analysis. The CONSORT diagram is shown in Fig. 2, and baseline patient characteristics are summarised in Table 1.

All 21 patients started buparlisib and 19 patients started radiotherapy. Fifteen (71%) patients had full compliance with treatment. Three patients discontinued treatment because of AEs (described below), 1 patient accidentally missed a dose of buparlisib, 1 patient discontinued treatment because of disease progression and 1 patient was replaced because of FMISO production failure.

### 3.1. MTD and safety assessment

No DLT was reported; therefore, buparlisib 100 mg OD was declared as the MTD. The safety analysis results are summarised in Table 2. In total, 114 AEs were experienced by 20 of 21 patients of which 103 (90%) were grade 2. One patient in the expansion cohort discontinued treatment because of worsening long-standing abdominal pain (unrelated to treatment). 94% of all AEs with any relation to treatment were grade 2 with only three grade 3 AEs deemed possibly related to treatment (2 fatigue and 1 hypoalbuminaemia). Most common treatment-related AEs per patient were fatigue (67%), nausea (24%) and decreased appetite (19%).

Five AEs, all grade 1, were specifically related to radiotherapy and included skin reaction in 3 patients and fatigue and cough in another patient. There was no reported acute oesophagitis or pneumonitis.

Four patients experienced serious adverse events. One patient (cohort 2) discontinued treatment due to grade 5 lower limb ischaemia, which was deemed unrelated to treatment due to long-standing vascular disease.

### Table 1

| Characteristics                              | Dose escalation phase | Expansion phase (n = 10) | Total (n = 21) |
|----------------------------------------------|-----------------------|--------------------------|---------------|
|                                              | Cohort 1 (n = 4)       | Cohort 2 (n = 4)         | Cohort 3 (n = 3) |               |
| Age [years]                                  | 64 (58–77)            | 72 (63–75)               | 68 (68–72)     | 68 (52–78)    | 69 (52–78)    |
| Gender                                       |                       |                          |               |               |
| Male                                         | 50 (2)                | 50 (2)                   | 33 (1)        | 20 (2)        | 33 (7)        |
| Female                                       | 50 (2)                | 50 (2)                   | 67 (2)        | 80 (8)        | 67 (14)       |
| Stage of disease                             |                       |                          |               |               |
| IV                                           | 100 (4)               | 100 (4)                  | 100 (3)       | 100 (10)      | 100 (21)      |
| ECOG performance status                      | 0                     | 0                        | 33 (1)        | 50 (5)        | 29 (6)        |
| 1                                            | 100 (4)               | 100 (4)                  | 67 (2)        | 50 (5)        | 71 (15)       |
| Tumour volume [mL]a                          | 111 (13–510)          | 135 (29–204)             | 54 (40–219)   | 99 (8–250)    | 101 (8–510)   |
| Histology                                    |                       |                          |               |               |
| Adenocarcinoma                               | 75 (3)                | 25 (1)                   | 33 (1)        | 60 (6)        | 52 (11)       |
| Squamous cell                                | 25 (1)                | 75 (3)                   | 67 (2)        | 40 (4)        | 48 (10)       |
| Previous treatment                           |                       |                          |               |               |
| Chemotherapy                                 | 50 (2)                | 50 (2)                   | 33 (1)        | 70 (7)        | 57 (12)       |
| Surgical treatment                           | 0                     | 0                        | 0             | 60 (6)        | 29 (6)        |
| Extrathoracic radiotherapy                   | 0                     | 25 (1)                   | 0             | 30 (3)        | 19 (4)        |
| Predominant clinical indication for radiotherapy |               |                          |               |               |
| Chest pain                                   | 25 (1)                | 0                        | 33 (1)        | 40 (4)        | 29 (6)        |
| Bronchial obstruction                        | 75 (3)                | 25 (1)                   | 0             | 10 (1)        | 24 (5)        |
| Cough                                        | 0                     | 25 (1)                   | 0             | 40 (4)        | 24 (5)        |
| Superior vena cava obstruction               | 0                     | 25 (1)                   | 0             | 0             | 5 (1)         |
| Solitary site of progression                 | 0                     | 25 (1)                   | 0             | 0             | 5 (1)         |
| Haemoptysis                                  | 0                     | 0                        | 33 (1)        | 0             | 5 (1)         |
| Left atrium invasion                         | 0                     | 0                        | 33 (1)        | 0             | 5 (1)         |
| Brachial plexus invasion                     | 0                     | 0                        | 0             | 10 (1)        | 5 (1)         |

Data are median (range) or % (number).

ECOG, Eastern Cooperative Oncology Group.

*a Tumour volume data were only available for patients evaluable for the imaging analysis.*
and symptoms of acute ischaemia preceded starting buparlisib. One patient (cohort 3) developed grade 3 lung infection (unrelated to treatment) and hypoalbuminaemia (possibly related to buparlisib) and discontinued treatment. Two patients (cohorts 1 and 2) experienced grade 3 lung infection (unrelated to treatment).

3.2. Tumour response to buparlisib

Fifteen patients were evaluable for tumour hypoxia analysis. As shown by the waterfall plot in Fig. 3, 10 (67%) of 15 patients were responders. Table 3 summarises the hypoxia response data. All cohort 1 patients were non-responders with 7% median HV increase. All cohort 2 patients were responders with 18% median HV decrease. In cohort 3 and the expansion cohort, 7 (77%) of 9 patients were responders with 20% median HV decrease. No correlation between tumour size and response was observed (Supplementary Fig. S1). Fig. 4 shows representative examples of FMISO PET-CT images for an expansion cohort patient.

pCT results are shown as supplementary data (Tables S1 and S2).

4. Discussion

We demonstrate that buparlisib, a pan class 1 PI3K inhibitor, is well tolerated with palliative thoracic radiotherapy and that this agent rapidly reduces tumour hypoxia.

Although in our study a palliative dose of radiation was used, the lack of any unexpected radiotherapy toxicity reported is encouraging for the safe combination of this class of agent with radical doses of radiation. Pre-clinical data demonstrate that PI3K inhibition radiosensitises tumours, at least in part, by alleviating

Table 2
Adverse events.

| Parameter                        | Dose group | Total (n = 21) |
|----------------------------------|------------|---------------|
|                                  | Cohort 1 [50 mg] (n = 4) | Cohort 2 [80 mg] (n = 4) | Cohort 3* [100 mg] (n = 13) |            |
| Total number of AE episodesb     | 19         | 17            | 78             | 114        |
| Patients with AEs                |            |               |                |            |
| ≥ 3 AEs                          | 4 (100)    | 4 (100)       | 12 (92)        | 20 (95)    |
| Grade ≥ 3 AEs                    | 1 (25)     | 2 (50)        | 4 (31)         | 7 (33)     |
| SAEs                             | 1 (25)     | 2 (50)        | 1 (8)          | 4 (19)     |
| Patients discontinued treatment because of AEs | 0 | 0 | 1 (8) | 1 (5) |
| SAEs                             | 0          | 1 (25)        | 1 (8)          | 2 (10)     |
| Patients experiencing treatment-related AEs^c | 2 (50) | 3 (75) | 9 (69) | 14 (67) |
| Fatigue                          | 1 (25)     | 1 (25)        | 3 (23)         | 5 (24)     |
| Nausea                           | 1 (25)     | 0             | 3 (23)         | 4 (19)     |
| Decreased appetite               | 0          | 0             | 3 (23)         | 3 (14)     |
| Constipation                     | 0          | 0             | 3 (23)         | 4 (19)     |
| Radiotherapy skin reaction       | 1 (25)     | 0             | 3 (23)         | 4 (19)     |
| Rash                             | 0          | 0             | 4 (31)         | 4 (19)     |
| Altered/depressed mood           | 0          | 0             | 3 (23)         | 3 (14)     |
| Dyspepsia                        | 0          | 1 (25)        | 1 (8)          | 2 (10)     |
| Hiccups                          | 0          | 0             | 2 (15)         | 2 (10)     |
| Oral candidiasis                 | 1 (25)     | 0             | 0              | 1 (5)      |
| Headache                         | 0          | 1 (25)        | 0              | 1 (5)      |
| Weight loss                      | 0          | 0             | 1 (8)          | 1 (5)      |
| Stomatitis                       | 0          | 0             | 1 (8)          | 1 (5)      |
| Personality change               | 0          | 0             | 1 (8)          | 1 (5)      |
| Dry skin                         | 0          | 0             | 1 (8)          | 1 (5)      |
| Hyperglycaemia                   | 0          | 0             | 1 (8)          | 1 (5)      |
| Hypophosphatemia                 | 0          | 0             | 1 (8)          | 1 (5)      |
| Vomiting                         | 0          | 0             | 1 (8)          | 1 (5)      |
| Cough                            | 0          | 0             | 1 (8)          | 1 (5)      |
| Nightmare                        | 0          | 0             | 1 (8)          | 1 (5)      |
| Total number of treatment-related AEs | 6          | 6             | 41             | 53         |
| Patients experiencing treatment-related SAEs |            |               |                |            |
| Hypoalbuminaemia                 | 0          | 0             | 1 (8)          | 1 (5)      |

Data are patient number (%).
AE, adverse event; SAE, serious adverse event.
* Cohort 3 includes patients in the dose escalation and expansion phases.
* AE episodes are shown only once per patient and if an AE occurrence was temporally associated with study participation, or if the grade of an AE which was present at baseline increased during study participation.
* Shown are AEs of all grades with possible, probable or definite relation to treatment with buparlisib and/or radiotherapy.
As hypoxia is predominantly a tumour-specific phenomenon, in principle, such agents are expected to preferentially radiosensitise tumours, as compared with normal tissues.

Trial accrual was challenging for numerous reasons. Patients with metastatic NSCLC requiring palliative radiotherapy were generally unwell with poor performance status and many were therefore ineligible for the study. Commonly, radiotherapy was indicated urgently and thus trial participation was clinically inappropriate. The high rate of AEs experienced by patients reflects this borderline fit and deteriorating patient group. The increasing use of targeted treatments for advanced NSCLC was a further challenge to recruitment, as was the fact that this was a single-centre study.

Despite the relatively small size of our study, the observation that buparlisib reduces tumour hypoxia supports pre-clinical data and therefore represents an important clinical proof-of-principle for this class of agents. The absence of such studies in the development of hypoxia modifiers previously may explain why numerous clinical trials have failed to demonstrate improvement in radiotherapy outcomes. A lack of sufficiently validated hypoxia biomarkers to enable selection of patients who would benefit from hypoxia treatment is further contributory. For example, in head and neck cancer, the hypoxia-targeting agents nimorazole and tirapazamine may have improved radiotherapy outcomes if predictive hypoxia biomarkers were used to select patients[23,24]. Therefore, to further develop PI3K inhibitors as radiosensitisers, it is important to also develop and incorporate hypoxia biomarkers into future study design.

As our data demonstrate a reduction in hypoxia after PI3K inhibition, it is hoped that combining such agents with radiotherapy may improve outcomes. To establish this, studies in the radical radiotherapy setting are required. As FMISO PET relies on tracer accumulation in viable tissues with oxygen tensions significantly below that at which radioresistance becomes a feature[25], it is

Table 3
Summary of FMISO PET-CT results.

| Cohort     | Number (%) of responders per cohort | TBR >1.4 volume | % change |
|------------|------------------------------------|-----------------|----------|
|            |                                    | First scan      | Second scan |        |
|            |                                    | Median [IQR]    | Median [IQR] | Median [IQR] |
| Cohort 1 (n = 3) | 0 | 44.4 [0.4 239] | 47.6 [0.4 233] | 7.1 [−2.5 14.3] |
| Cohort 2 (n = 3) | 3 (100) | 51.3 [1.3 99.5] | 42.2 [1.1 75.6] | −17.6 [−24.1 –16.7] |
| Cohort 3 (n = 9) | 7 (77) | 33.1 [6.9 43.7] | 25.4 [4.9 42.0] | −19.9 [−41.9 –14.6] |
| Overall (n = 15) | 10 (67) | 40.4 [3.3 67.5] | 27.6 [3.5 52.5] | −16.8 [−37.1 7.1] |

Data are number (%) or median (IQR). Cohort 3 includes patients in the dose escalation and expansion phases. FMISO, 18F-fluoromisonidazole; PET, positron-emission tomography; TBR, tumour-to-blood ratio; IQR, interquartile range.
expected that the reduction in HV detected in our study is likely to result in improved tumour radiation response. This is supported by the observation that high FMISO uptake in patients with NSCLC is associated with significantly worse outcomes after radiotherapy [18]. Furthermore, given that PI3K inhibition is known to improve tumour intrinsic radiosensitisation, the effects would be anticipated to be more pronounced than through hypoxia reduction alone. Encouragingly, early phase studies combining inhibitors of downstream signalling targets of PI3K with radiotherapy, such as the AKT inhibitor nelfinavir, have reported promising response rates and outcomes in rectal and pancreatic cancer [26–28]. Hahn et al. demonstrated that upstream inhibition of Ras with a farnesyltransferase inhibitor resulted in impressive complete response rates in NSCLC and head and neck cancer when combined with radical radiotherapy [29].

Although, we observed a reduction in tumour hypoxia in most patients, this did not always correspond with increased tumour perfusion. This may reflect the technical challenges of performing pCT in our patient population, namely tumours were often only partly imaged because of large size with significant motion artefact. Interestingly, this may also perhaps represent the fact that buparlisib inhibits tumour mitochondrial oxygen consumption [14], and so changes in hypoxia and perfusion may, at least in part, be independent phenomena. In fact, mathematical modelling suggests that reducing oxygen consumption may be more effective in addressing tumour hypoxia compared with strategies aimed solely at improving oxygen delivery [30].

5. Conclusion
Overall, the results from this trial demonstrate that PI3K inhibition reduces tumour hypoxia in patients with NSCLC and when combined with thoracic radiotherapy is well tolerated. This study supports the development of clinical trials combining this class of agent with radical radiotherapy with the aim of improving outcomes in NSCLC.

Conflict of interest statement
The authors have no conflicts of interests to declare.

Acknowledgements
The authors would like to thank the patients and their relatives who took part in the BKM120 trial and the staff at the Oxford University Hospitals NHS Foundation Trust. This work was supported by Cancer Research UK (C34326/A15163) with further funding support from the CRUK and EPSRC Oxford Cancer Imaging Centre, the Oxford ECMC, the NIHR and the CRUK Oxford Centre. The trial was sponsored by the University of Oxford and managed by the Oncology Clinical Trials Office. Novartis Pharmaceuticals UK Ltd provided buparlisib. The authors acknowledge the NCRI CTRad Working Group for advice during protocol development and members of the Independent Early Phase Trials Oversight Committee who provided support and guidance.

D.M. is funded by a National Institute for Health Research (NIHR)/Health Education England (HEE) Clinical Lectureship (ICA-CL-016-02-009). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, HEE or the Department of Health and Social Care. G.H. is supported by a Cancer Research UK Clinician Scientist Awards (C34326/A13092 and C34326/A19590). J.F. was supported by Cancer Research UK Career Development Fellowship (C17203). V.S. is supported by CRUK (C5529/A16895).

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejca.2019.03.015.

References
[1] Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 2014;112:140–4. https://doi.org/10.1016/j.radonc.2013.06.104.
[2] Auperin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Founier P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90. https://doi.org/10.1200/JCO.2009.26.2543.
[3] Machtay M, Paulous R, Moughan J, Komaki R, Bradley Jeffrey, Choy H, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 2012;7:716–22. https://doi.org/10.1097/JTO.0b013e3182429682.
[4] McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The Ras signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22:5866. https://doi.org/10.1038/sj.onc.1206699.
[5] Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997;21:127–43.
[6] Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885–92.
[7] Gupta AK, Soto DE, Feldman MD, Goldsmith JD, Mick R, Hahn SM, et al. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004;182:151–62.
[8] Kim I-A, Bae S-S, Fernandes A, Wu J, Muschel RJ, McKenna WG, et al. Selective inhibition of ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005;65:7902–10. https://doi.org/10.1158/0008-5472.CAN-05-0513.
[9] Quyum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, et al. Tumor vascular changes mediated by inhibition of
oncogenic signaling. Cancer Res 2009;69:6347–54. https://doi.org/10.1158/0008-5472.CAN-09-0657.

[10] Cerniglia GJ, Porc N, Tsai JH, Schultz S, Mick R, Choe R, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009;4:e6539. https://doi.org/10.1371/journal.pone.0006539.

[11] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–57. https://doi.org/10.1038/35025220.

[12] Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638–48. https://doi.org/10.1259/0007-1285-26-312-638.

[13] Fokas E, Im JH, Yameen S, Stratford M, Beech J, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012;72:239–48. https://doi.org/10.1158/0008-5472.CAN-11-2263.

[14] Kelly CJ, Hussien K, Fokas E, Kannan P, Shipley RJ, Ashton TM, et al. Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol 2014;111:72–80. https://doi.org/10.1016/j.radonc.2014.02.007.

[15] Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282–90. https://doi.org/10.1200/JCO.2011.36.1360.

[16] Vansteenkiste JF, Canon J-L, De Braud F, Grossi F, De Pas T, Gray JE, et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer. J Thorac Oncol 2015;10:1319–27. https://doi.org/10.1097/JTO.0000000000000607.

[17] Pistilli B, Phaard T, Urruticoechea A, Farci D, Kong A, Bachelot T, et al. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat 2018;168:357–64. https://doi.org/10.1007/s10549-017-4596-7.

[18] Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-fluoromisonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253–60.

[19] Xu Z, Li X-F, Zou H, Sun X, Shen B. 18F-Fluoromisonidazole in tumor hypoxia imaging. Oncotarget 2017;8:94969–79. https://doi.org/10.18632/oncotarget.21662.

[20] Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54:201–7. https://doi.org/10.2967/jnumed.112.109330.

[21] Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199–212.

[22] Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J Off J North Am Spine Soc 2007;7:541–6. https://doi.org/10.1016/j.spinee.2007.01.008.

[23] Toustrup K, Sørensen BS, Lassen P, Winf C, Alner J, Overgaard J, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122–9. https://doi.org/10.1016/j.radonc.2011.09.010.

[24] Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098–104. https://doi.org/10.1200/JCO.2005.05.2878.

[25] Rasey JS, Nelson NJ, Cahn E, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301–8.

[26] Buijsen J, Lammering G, Jansen R,LH, Beets WL, Wals J, Sosef M, et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol 2013;107:184–8. https://doi.org/10.1016/j.radonc.2013.03.023.

[27] Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26:2699–706. https://doi.org/10.1200/JCO.2007.15.2355.

[28] Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, et al. ARCH: a phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 2016;119:306–11. https://doi.org/10.1016/j.radonc.2016.03.021.

[29] Hahn SM, Bernhard EJ, Regine W, Mohiuddin M, Haller DG, Stevenson JP, et al. A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced rectal cancer. Radiother Oncol 2008;8:2065–72.

[30] Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol Stockholm 1995;34:313–6.